Literature DB >> 22547750

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.

Pierre Cochat1, Sally-Anne Hulton, Cécile Acquaviva, Christopher J Danpure, Michel Daudon, Mario De Marchi, Sonia Fargue, Jaap Groothoff, Jérôme Harambat, Bernd Hoppe, Neville V Jamieson, Markus J Kemper, Giorgia Mandrile, Martino Marangella, Stefano Picca, Gill Rumsby, Eduardo Salido, Michael Straub, Christiaan S van Woerden.   

Abstract

Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary excretion of oxalate, causing recurrent urolithiasis and nephrocalcinosis. As glomerular filtration rate declines due to progressive renal involvement, oxalate accumulates leading to systemic oxalosis. The diagnosis is based on clinical and sonographic findings, urine oxalate assessment, enzymology and/or DNA analysis. Early initiation of conservative treatment (high fluid intake, pyridoxine, inhibitors of calcium oxalate crystallization) aims at maintaining renal function. In chronic kidney disease Stages 4 and 5, the best outcomes to date were achieved with combined liver-kidney transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547750     DOI: 10.1093/ndt/gfs078

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  92 in total

1.  Characteristics of the genotype and phenotype in Chinese primary hyperoxaluria type 1 populations.

Authors:  Fangzhou Zhao; Jun Li; Lei Tang; Chunming Li; Wenying Wang; Chen Ning
Journal:  Urolithiasis       Date:  2020-06-18       Impact factor: 3.436

Review 2.  Recent advances in the identification and management of inherited hyperoxalurias.

Authors:  David J Sas; Peter C Harris; Dawn S Milliner
Journal:  Urolithiasis       Date:  2018-12-10       Impact factor: 3.436

3.  Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

Authors:  Xiaojing Tang; Nikolay V Voskoboev; Stacie L Wannarka; Julie B Olson; Dawn S Milliner; John C Lieske
Journal:  Am J Nephrol       Date:  2014-04-26       Impact factor: 3.754

4.  Skin microvascular dysfunction as an early cardiovascular marker in primary hyperoxaluria type I.

Authors:  Alexandra Bruel; Justine Bacchetta; Tiphanie Ginhoux; Christelle Rodier-Bonifas; Anne-Laure Sellier-Leclerc; Bérengère Fromy; Pierre Cochat; Dominique Sigaudo-Roussel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

Review 5.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

6.  Identification of 8 novel gene variants in primary hyperoxaluria in 21 Chinese children with urinary stones.

Authors:  Lei He; Guofeng Xu; Xiaoliang Fang; Houwei Lin; Maosheng Xu; Yongguo Yu; Hongquan Geng
Journal:  World J Urol       Date:  2018-11-28       Impact factor: 4.226

Review 7.  Primary hyperoxaluria type 1: practical and ethical issues.

Authors:  Pierre Cochat; Jaap Groothoff
Journal:  Pediatr Nephrol       Date:  2013-03-14       Impact factor: 3.714

Review 8.  Building on evidence to improve patient care.

Authors:  Evelien Snauwaert; Johan VandeWalle; Evi V Nagler; Wim Van Biesen
Journal:  Pediatr Nephrol       Date:  2016-12-09       Impact factor: 3.714

Review 9.  The Kidney in Pediatric Liver Disease.

Authors:  Robyn Greenfield Matloff; Ronen Arnon
Journal:  Curr Gastroenterol Rep       Date:  2015-09

10.  Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.

Authors:  Fang Zhao; Eric J Bergstralh; Ramila A Mehta; Lisa E Vaughan; Julie B Olson; Barbara M Seide; Alicia M Meek; Andrea G Cogal; John C Lieske; Dawn S Milliner
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-10       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.